Additionally, combining anti-PD-1 with reducing HIF1A concentrations by pharmacologically inhibiting Axl decreases the main tumour and metastatic loads in a preclinical model of HER2+ breast cancer, indicating a viable treatment strategy in BC (39). This evidence concerns the gene PDCD1 and neoplasm.